Intercept to Announce First Quarter 2021 Financial Results on May 6, 2021
Intercept Pharmaceuticals (Nasdaq:ICPT) will announce its Q1 2021 financial results on May 6, 2021, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq:ICPT) will announce its Q1 2021 financial results on May 6, 2021, before the market opens. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results. The call will be accessible via the company's investor page and through international dialing options. Intercept focuses on novel therapeutics for progressive non-viral liver diseases such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH), with operations in the U.S., Europe, and Canada.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was -0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2021 financial results prior to market open on Thursday, May 6, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (888) 517-2458 (toll-free domestic) or (847) 413-3538 (international) passcode 9873 994. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Investor inquiries:
investors@interceptpharma.com
Media inquiries:
media@interceptpharma.com
Source: Intercept Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.